AP5

Daniel Monaghan

doi:10.1016/B978-008055232-3.61242-5

AP5

Daniel Monaghan

Pharmacology & Experimental Neuroscience (PEN)

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

D-AP5 was the first NMDA receptor antagonist with sub-micromolar potency.

Original language	English (US)
Title of host publication	xPharm
Subtitle of host publication	The Comprehensive Pharmacology Reference
Publisher	Elsevier Inc.
Pages	1-3
Number of pages	3
ISBN (Print)	9780080552323
DOIs	https://doi.org/10.1016/B978-008055232-3.61242-5
State	Published - 2007

ASJC Scopus subject areas

Pharmacology, Toxicology and Pharmaceutics(all)

Access to Document

10.1016/B978-008055232-3.61242-5

Cite this

@inbook{3fe3e7032158418faa1d14ccecd93ef6,

title = "AP5",

abstract = "D-AP5 was the first NMDA receptor antagonist with sub-micromolar potency.",

author = "Daniel Monaghan",

year = "2007",

doi = "10.1016/B978-008055232-3.61242-5",

language = "English (US)",

isbn = "9780080552323",

pages = "1--3",

booktitle = "xPharm",

publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - AP5

AU - Monaghan, Daniel

PY - 2007

Y1 - 2007

N2 - D-AP5 was the first NMDA receptor antagonist with sub-micromolar potency.

AB - D-AP5 was the first NMDA receptor antagonist with sub-micromolar potency.

UR - http://www.scopus.com/inward/record.url?scp=84883973462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883973462&partnerID=8YFLogxK

U2 - 10.1016/B978-008055232-3.61242-5

DO - 10.1016/B978-008055232-3.61242-5

M3 - Chapter

AN - SCOPUS:84883973462

SN - 9780080552323

SP - 1

EP - 3

BT - xPharm

PB - Elsevier Inc.

ER -

AP5

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this